submit focu fda approv
process increas pt
ahead axnx earn releas updat sales/
loss per share lp estim exhibit
vs consensu rais rel valuat
pt reiter buy
estim regulatori approv timelin updat
revenue/lp estim report exhibit
vs prior compar consensu
model gross margin
unchang compar consensu note compani
submit posit top-line data pivot artisan trial link
well full-bodi mri data link fda
support literature-bas pma believ may receiv fda approv
literature-bas pma note compani still retain
option file tradit clinic base pma expect
fda approv continu model axnx entranc us
snm market adjust model appropri futur fda
approv updat intern r-snm system recent receiv ce mark
approv full-bodi mri
thesi believ snm market could grow
estim compound-annual-growth-rate sale
come us technolog innov axon key competit
edg r-snm lifespan longer medtron
buy interstim smaller volum full-bodi mri
compat well eas use physician patient interfac
could give critic advantag market otherwis stagnant
term innov thesi predic axon quickli grow
revenu meaning share captur assert
mount effect competit respons henc axon
speed market key rate share buy
valuat risk pt arriv appli ev/sal
multipl estim revenu month henc exhibit
ev/sal multipl in-lin faster grow smid med-tech
compani median ev/sal multipl averag
exhibit continu pg
tr target
sale multipl peer group provid surrog forward multipl risk
includ fda approv delay could narrow competit window promis
modern devic and/or unforeseen hurdl quickli build larg us
sale forc and/or unanticip friction marketplac
page
est
est
est
page
est
est
est
page
 debt
share
price
note entellu medic multipl calcul use transact valu entellu acquir
buy entellu medic mdwd futur sale strh estim other consensu
page
expens margin analysi sale
revenu
page
axon develop sacral neuromodul system sn use third-lin treatment
condit urinari incontin wet dri nonobstruct urinari retent fecal
incontin compani found headquart irvin ca
believ snm market could grow estim
compound-annual-growth-rate sale come us technolog innov axon
key competit edg r-snm lifespan longer medtron
buy interstim smaller volum full-bodi mri compat well eas
use physician patient interfac could give critic advantag market
otherwis stagnant term innov thesi predic axon quickli grow
revenu meaning share captur assert mount effect
competit respons henc axon speed market key rate share
valuat risk
pt arriv appli ev/sal multipl estim revenu
month henc ev/sal multipl in-lin faster grow smid med-tech compani
median ev/sal multipl averag sale multipl
peer group provid surrog forward multipl risk includ fda approv delay
could narrow competit window promis modern devic
and/or unforeseen hurdl quickli build larg us sale forc and/or unanticip
friction marketplac
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
